… for chronic GVHD … the graft, and absence of methotrexate in PBSC transplantation [21, 46,
50, 52, 53, 54]. Early reports of umbilical blood stem cell grafting suggest lower rates of chronic …

Chronic graft-versus-host disease (GVHD) is a frequent and potentially life-threatening
complication of allogeneic hematopoietic stem cell transplantation. Increased transplantation of …

Chronic graft-versus-host disease (GVHD) remains a common and potentially life-threatening
complication of allogeneic hematopoietic stem cell transplantation (HCT). The 2-year …

Chronic graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in long-term
survivors of allogeneic stem cell transplantation. The immunopathogenesis of chronic …

… Of the 60–70% patients receiving human leucocyte antigen (HLA)-identical sibling marrow
grafts or alternative donor marrow grafts who survive beyond day 100 develop chronic GvHD (…

… Occurring a minimum of 100 days following stem cell transplantation, approximately 50%
of patients will experience some degree of chronic GVHD. Host-reactive lymphocytes of donor …

As more patients undergo and survive allogeneic stem cell transplantation more attention is
being focused on the study of chronic graft versus host disease. Although the …

… a recipient, the resulting inflammation and immune dysregulation can lead to chronic graft-versus-host
disease (GVHD). Chronic GVHD is the most common long-term complication after …

A joint working group established by the Haemato‐oncology subgroup of the B ritish C
ommittee for S tandards in H aematology ( BCSH ) and the B ritish S ociety for B one M arrow T …

… -stimulating factor–mobilized peripheral blood stem cell donor grafts and successful treatment
of older recipients, chronic graft-versus-host disease (cGVHD) has emerged as the major …